AnaptysBio, Inc. (NASDAQ:ANAB) Receives $35.11 Average Price Target from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $35.11.

Several analysts recently commented on ANAB shares. Truist Financial reduced their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Wells Fargo & Company boosted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th.

AnaptysBio Stock Down 1.4 %

Shares of NASDAQ ANAB opened at $18.19 on Friday. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $41.31. The company has a market cap of $557.83 million, a PE ratio of -2.99 and a beta of 0.02. The business’s 50 day moving average price is $17.00 and its two-hundred day moving average price is $22.19.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. As a group, research analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has initiated a stock repurchase program on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc acquired 65,184 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 33.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in ANAB. Wellington Management Group LLP increased its stake in AnaptysBio by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company’s stock valued at $880,000 after acquiring an additional 528 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 936 shares in the last quarter. Rhumbline Advisers lifted its position in shares of AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock worth $398,000 after buying an additional 1,111 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in AnaptysBio by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 1,359 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.